{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:03:54Z","timestamp":1795086234312,"version":"4.10.2"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":4330,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.7861\/clinmedicine.12-3-261","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T18:27:28Z","timestamp":1361298448000},"page":"261-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Glucocorticoids in bone and joint disease: the good, the bad and the uncertain"],"prefix":"10.1016","volume":"12","author":[{"given":"Mark S.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.12-3-261_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom","volume":"93","author":"van Staa","year":"2000","journal-title":"QJM"},{"key":"10.7861\/clinmedicine.12-3-261_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.7861\/clinmedicine.12-3-261_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/CS20040070","article-title":"Sensitivity of bone to glucocorticoids","volume":"107","author":"Cooper","year":"2004","journal-title":"Clin Sci"},{"key":"10.7861\/clinmedicine.12-3-261_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrrheum.2009.259","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"6","author":"Compston","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.7861\/clinmedicine.12-3-261_bib5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.12-3-261_bib6","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.12-3-261_bib7","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1210\/jc.2009-1412","article-title":"11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation","volume":"94","author":"Cooper","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.12-3-261_bib8","first-page":"57","article-title":"Absence of cushingoid phenotype in a patient with Cushing\u2019s disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.12-3-261_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S8756-3282(00)00344-6","article-title":"Expression and functional consequences of 11b-hydroxysteroid dehydrogenase activity in human bone","volume":"27","author":"Cooper","year":"2000","journal-title":"Bone"},{"key":"10.7861\/clinmedicine.12-3-261_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1096\/fj.01-0582com","article-title":"Pre-receptor regulation of glucocorticoid action by 11b-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation","volume":"16","author":"Rabbitt","year":"2002","journal-title":"FASEB J"},{"key":"10.7861\/clinmedicine.12-3-261_bib11","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1210\/jc.2003-022025","article-title":"11b-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.12-3-261_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","article-title":"Osteoblastic 11b-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure","volume":"17","author":"Cooper","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.7861\/clinmedicine.12-3-261_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1474-9726.2009.00545.x","article-title":"Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice","volume":"9","author":"Weinstein","year":"2010","journal-title":"Aging Cell"},{"key":"10.7861\/clinmedicine.12-3-261_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/JOE-08-0568","article-title":"Bone loss in inflammatory disorders","volume":"201","author":"Hardy","year":"2009","journal-title":"J Endocrinol"},{"key":"10.7861\/clinmedicine.12-3-261_bib15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1359\/jbmr.2001.16.6.1037","article-title":"Modulation of 11b-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation","volume":"16","author":"Cooper","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.7861\/clinmedicine.12-3-261_bib17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2008.090662","article-title":"Local and systemic glucocorticoid metabolism in inflammatory arthritis","volume":"67","author":"Hardy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-3-261_bib18","doi-asserted-by":"crossref","first-page":"R","DOI":"10.1186\/ar1993","article-title":"Differential expression, function and response to inflammatory stimuli of 11b-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation","volume":"8","author":"Hardy","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.7861\/clinmedicine.12-3-261_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra020529","article-title":"Corticosteroid insufficiency in acutely ill patients","volume":"348","author":"Cooper","year":"2003","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.12-3-261_bib20","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/keq212","article-title":"The 11beta-hydroxysteroid dehydrogenase enzymes\u2013arbiters of the effects of glucocorticoids in synovium and bone","volume":"49","author":"Raza","year":"2010","journal-title":"Rheumatology"},{"key":"10.7861\/clinmedicine.12-3-261_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/en.2011-1398","article-title":"11beta-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice","volume":"153","author":"Coutinho","year":"2012","journal-title":"Endocrinology"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824025399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824025399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.12-3-261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:37:25Z","timestamp":1761460645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824025399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1470211824025399"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.12-3-261","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoids in bone and joint disease: the good, the bad and the uncertain","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.12-3-261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2012. All rights reserved.","name":"copyright","label":"Copyright"}]}}